高级搜索

力达霉素联合硼替佐米的抗骨髓瘤作用及对MAPKs表达的影响

甄永占, 纪春梅, 郝晓方, 赵毓芳, 章广玲, 吕翠平

甄永占, 纪春梅, 郝晓方, 赵毓芳, 章广玲, 吕翠平. 力达霉素联合硼替佐米的抗骨髓瘤作用及对MAPKs表达的影响[J]. 肿瘤防治研究, 2014, 41(05): 353-357. DOI: 10.3971/j.issn.1000-8578.2014.05.001
引用本文: 甄永占, 纪春梅, 郝晓方, 赵毓芳, 章广玲, 吕翠平. 力达霉素联合硼替佐米的抗骨髓瘤作用及对MAPKs表达的影响[J]. 肿瘤防治研究, 2014, 41(05): 353-357. DOI: 10.3971/j.issn.1000-8578.2014.05.001
ZHEN Yongzhan, JI Chunmei, HAO Xiaofang, ZHAO Yufang, ZHANG Guangling, LV Cuiping. Lidamycin Enhances Sensitivity of Multiple Myeloma to Bortezomid by Modulating Expression of Mitogen-activated Protein Kinases[J]. Cancer Research on Prevention and Treatment, 2014, 41(05): 353-357. DOI: 10.3971/j.issn.1000-8578.2014.05.001
Citation: ZHEN Yongzhan, JI Chunmei, HAO Xiaofang, ZHAO Yufang, ZHANG Guangling, LV Cuiping. Lidamycin Enhances Sensitivity of Multiple Myeloma to Bortezomid by Modulating Expression of Mitogen-activated Protein Kinases[J]. Cancer Research on Prevention and Treatment, 2014, 41(05): 353-357. DOI: 10.3971/j.issn.1000-8578.2014.05.001

力达霉素联合硼替佐米的抗骨髓瘤作用及对MAPKs表达的影响

基金项目: 河北省自然科学基金资助项目(H2012401030)
详细信息
    作者简介:

    甄永占(1970-),女,博士,副教授,主要从事肿瘤分子药理学研究

  • 中图分类号: R733.3

Lidamycin Enhances Sensitivity of Multiple Myeloma to Bortezomid by Modulating Expression of Mitogen-activated Protein Kinases

  • 摘要: 目的 研究力达霉素(lidamycin, LDM)联合硼替佐米(bortezomib, BZM)的抗骨髓瘤作用及对丝裂原活化蛋白激酶(Mitogen-activated protein kinases, MAPKs)的影响,并探讨MAPKs在两药联合抗骨髓瘤中的作用。方法 选取适当的药物浓度和通路抑制剂浓度,MTS法检测细胞增殖情况;Western blot 检测相关蛋白及蛋白磷酸化水平。结果 BZM能增强LDM对骨髓瘤细胞的增殖抑制作用,LDM 激活c-Jun氨基末端激酶(c-Jun NH2-terminal kinase, JNK)、p38 MAPK的表达和细胞外信号调节激酶(Extracellular signal regulated rotein kinase, ERK),两药联合后可使JNK和p38 MAPK的激活显著增强,而ERK的激活显著下降。JNK抑制剂(SP600125)、p38抑制剂(SB203580)和MEK抑制剂(U0126) 3种抑制剂单独作用对细胞的增殖抑制作用均不明显,但SP600125或SB203580分别与LDM联合BZM合用后均降低了两药联合对细胞的增殖抑制作用,而U0126与LDM联合BZM合用后提高了两药联合对细胞的增殖抑制作用。结论 LDM通过进一步激活JNK、p38 MAPK和降低ERK的激活来增强BZM抗骨髓瘤敏感度。

     

    Abstract: Objective To investigate the effect of lidamycin (LDM) combined with bortezomid (BZM) against multiple myeloma and the activative role of mitogen-activated protein kinases (MAPKs) in cell death after the combination treatment. Methods By selecting the appropriate concentrations of drugs and pathway inhibitors, cell proliferation was detected by MTS. The expression of JNK, p38 MAPK and ERK were detected by Western blot. Results LDM synergistically enhanced BZM-induced proliferation inhibition against human myeloma U266 cells. JNK, the expression of p38 MARK and ERK were activated by LDM. The activation of JNK and p38 MAPK were remarkably increased while ERK activation was decreased by the combined LDM and BZM. The inhibitors of JNK, p38 MAPK and MEK had no signifi cant effect on cell proliferation. JNK inhibitor (SP600125) or p38 MAPK inhibitor (SB203580) could reverse LDM plus BZM induced growth inhibition, conversely. MEK inhibitor (U0126) could synergistically enhance LDM plus BZM induced growth inhibition in U266 cells. Conclusion LDM greatly enhanced the sensitivity of multiple myeloma to BZM by further increasing the activation of JNK and p38 MAPK and decreasing the activation of ERK in U266 cells.

     

  • [1] Zeng Z, Zheng L, Lin J, et al. Successful bortezomib treatment in combination with dexamethasone and thalidomide for previously untreated epidural plasmacytoma[J]. Oncol Lett,2012,3(3):557-9.
    [2] Leiba M, Jakubikova J, Klippel S, et al.. Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents[J]. Br J Haematol, 2012,157(6):718-31.
    [3] Zhen YS, Xue YC, Shao RG. Antitumor activity of the new enediyne antibiotic C1027[J]. Zhongguo Kang Sheng Su Za Zhi,1994,19(2):164-8.[甄永苏, 薛玉川, 邵荣光. 烯二 炔类新抗生素C1027的抗肿瘤作用研究[J]. 中国抗生素杂志,1994,19(2):164-8.]
    [4] Zhong GS, Guo XF, Zhang SH, et al. Optimization of the assembly efficiency for lidamycin chromophore bound to its apoprotein: a case study using orthogonal array[J]. Biomed Environ Sci, 2011,24(6):602-7.
    [5] Zhang Q, Liu XJ, Hu L, et al. Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy[J]. Int J Mol Med,2012,29(3):409-15.
    [6] Zhen HY, He QH, Zhen YZ, et al.. Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct4, Sox2 and Myc[J]. Invest New Drugs,2011,29(6):1188-97.
    [7] Zhen YZ, Lin YJ, Shang BY, et al. Enediyne lidamycin induces apoptosis in human multiple myeloma cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase[J]. Int J Hematol,2009,90(1):44-51.
    [8] Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions[J]. Endocr Rev,2001,22(2):153-83.
    [9] Huang P, Han J, Hui L. MAPK signaling in inflammationassociated cancer development[J]. Protein Cell,2010,1(3):218-26.
    [10] Lu Z, Xu S. ERK1/2 MAP kinases in cell survival and apoptosis[J]. IUBMB Life,2006,58(11):621-31.
    [11] Wen J, Cheng HY, Feng Y, et al. p38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells[J]. Br J Haematol,2008,140(2):169-80.
    [12] Zhang B,Wang X,Cai F,et al. Antitumor properties of salinomycin on cisplatin-resistant human ovarian cancer cells in vitro and in vivo: involvement of p38 MAPK activation[J]. Oncol Rep,2013,29(4):1371-8.
    [13] Guo R,Lin J,Xu W, et al. Hydrogen sulfi de attenuates doxorubicininduced cardiotoxicity by inhibition of the p38 MAPK pathway in H9c2 cells [J]. Int J Mol Med,2013, 31(3):644-50.
计量
  • 文章访问数:  1551
  • HTML全文浏览量:  513
  • PDF下载量:  702
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-03-20
  • 修回日期:  2013-04-28
  • 刊出日期:  2014-05-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭